Quick answer
Medical cannabis is not an accepted long-term treatment for glaucoma. It can temporarily lower intraocular pressure (IOP), but the effect lasts only three to four hours. That means a person would need to consume cannabis six to eight times a day, including through the night, to maintain any pressure reduction. This regimen is impractical, costly, and often causes side effects such as low blood pressure, dizziness, and impaired cognition.
Why glaucoma requires constant pressure control
Glaucoma damages the optic nerve, usually because fluid builds up in the front of the eye and raises pressure. To prevent irreversible vision loss, IOP must be kept in a target range around the clock. Traditional treatments — prescription eye drops, laser procedures, and surgery — are designed to lower pressure continuously for 24 hours. Cannabis does not offer that sustained effect.
What research shows about cannabis and eye pressure
Studies in the 1970s found that smoking or ingesting tetrahydrocannabinol (THC), the active compound in cannabis, reduced IOP by about 25%. However, that reduction peaked quickly and faded within a few hours. Later research with synthetic THC and oral formulations showed similar problems: a short window of action and significant side effects at the doses needed.
Why it fails as maintenance therapy
For a chronic condition like glaucoma, the goal is stable eye pressure during sleep and wakefulness. Since cannabis would need to be taken every three to four hours, this creates a treatment burden that most patients cannot sustain. More importantly, frequent cannabis use can cause unpredictable absorption, especially with edibles or tinctures. The lack of standardized dosing makes it impossible to titrate a reliable amount. Also, recreational or medical cannabis products vary greatly in THC content, making consistent eye pressure control even harder.
Potential role in advanced or refractory glaucoma
Some researchers have looked at cannabis as an option for patients who do not respond to standard treatments or who cannot tolerate conventional medications. A small number of patients may benefit from short-term IOP relief while awaiting surgery. But no major ophthalmology organization currently recommends cannabis as a primary or secondary glaucoma therapy. The American Academy of Ophthalmology states that cannabis lowers intraocular pressure, but not enough to be a dependable long-term treatment.
The convenience factor
In states where medical cannabis is legal, patients can obtain products through mail-order delivery, dispensaries, or even online pickup. Convenience has become a deciding factor for some patients who are frustrated with daily eye drops or invasive procedures. Yet convenience does not overcome the fundamental problem: cannabis is not a 24-hour ocular hypotensive agent. Frequent dosing can interfere with daily life, and the sedating effects can be dangerous for older adults who may already be at risk for falls. A patient who values convenience may actually find nightly eye drops more practical than maintaining a six-times-a-day cannabis schedule.
Talk to your ophthalmologist before changing treatment
Glaucoma is a serious, lifelong disease. Stopping prescribed therapy to try cannabis can cause rapid vision loss. If you are considering medical marijuana for glaucoma, have an open conversation with your eye doctor. A professional can help you weigh the evidence, check for interactions with your current medicines, and recommend other approaches that offer safer, more consistent pressure control.